Chester A. Mathis

Psychiatry and Mental health · 2003–2016

A researcher in the Science corpus: 14 papers; trusts 2 researchers and is trusted by 6 researchers here, as inferred from the citation graph.

Subfields

• Psychiatry and Mental health — 79 citations into it; #643 of 1,338 by trust here, #16 by citations
• Physiology — 77 citations into it; #654 of 2,276 by trust here, #57 by citations

Whom Chester A. Mathis trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. William E. Klunk
2. H. Braak

Who trusts Chester A. Mathis overall

1. Clifford R. Jack Jr.
2. Randy L. Buckner
3. William E. Klunk
4. Anne M. Fagan
5. Mark A. Mintun

Papers from Chester A. Mathis's perspective

Ordered by how strongly the researchers Chester A. Mathis trusts endorse each paper. Same corpus, a different order for every researcher.

1. Neuropathological stageing of Alzheimer-related changes
2. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B (Journal of Cerebral Blood Flow and Metabolism)
3. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia (Proceedings of the National Academy of Sciences of the United States of America)
4. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. (Journal of Medicinal Chemistry)
5. Functional connectivity in the resting brain: A network analysis of the default mode hypothesis (Proceedings of the National Academy of Sciences of the United States of America)
6. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain (NeuroImage)
7. A new look at the statistical model identification
8. Mild cognitive impairment (The Lancet)
9. Cortical networks for working memory and executive functions sustain the conscious resting state in man. (Brain Research Bulletin)
10. PET of brain amyloid and tau in mild cognitive impairment. (New England Journal of Medicine)

Their papers

• Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease (2009) — 740 citations
• Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) — 1,062 citations
• Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue (2015) — 615 citations
• 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. (2008) — 936 citations
• Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly (2008) — 1,100 citations
• Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease (2008) — 959 citations
• β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease (2007) — 745 citations
• [11C]PIB in a nondemented population (2006) — 687 citations
• Potential antecedent marker of Alzheimer disease (2006) — 641 citations
• Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans (2006) — 946 citations
• Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory (2005) — 2,123 citations
• Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B (2005) — 718 citations
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B (2004) — 4,543 citations
• Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. (2003) — 978 citations